Results 101 to 110 of about 149 (148)
MiR‐29a/b Suppresses CD8+ T Cell Effector Function and Intestinal Inflammation
Exploration, EarlyView.Our findings suggest that miR‐29a/b is a critical regulator of CD8+ T cells, possibly via the Ifng‐JAK‐STAT signal in IBD patients and the upregulation of miR‐29a/b relieves the development of significant inflammation in the colon of DSS‐induced colitis‐affected mice.
Yingying Lin +27 more
wiley +1 more source
Somatic cell reprogramming for Parkinson's disease treatment
Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley +1 more source
Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions
Ibrain, EarlyView.Alzheimer's disease treatment is evolving rapidly, with emerging strategies targeting multiple disease pathways. This graphical abstract highlights the shift from traditional therapies to innovative approaches that hold promise for improving outcomes.
Tapas Kumar Mohapatra +4 more
wiley +1 more source
Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions
International Journal of Cancer, EarlyView.Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner +3 more
wiley +1 more source
Therapeutic targeting of chromatin alterations in leukemia and solid tumors
International Journal of Cancer, EarlyView.Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner +7 more
wiley +1 more source
International Journal of Cancer, EarlyView.What's New? Currently, no published data on homologous recombination deficiency (HRD) testing in the setting of molecular tumor boards exist. This study in a cohort of 237 patients encompassing 24 different tumor entities assessed by a molecular tumor board shows that inactivating alterations of BRCA1/2 are not always associated with an elevated ...
Christoph Schubart +26 more
wiley +1 more source
International Journal of Cancer, EarlyView.What's New? Circulating tumor cells can offer insights into treatment responses and metastatic recurrence, but current analysis methods are limited. Here, the authors tested a newly developed mass cytometry panel comprising biomarkers such as γH2AX and RAD51 in longitudinally monitored metastatic breast cancer patients.
Kathrin Niedermayer +17 more
wiley +1 more source
iMetaOmics, EarlyView.This narrative review uniquely addresses how gut microbiota‐derived metabolites mediate overlapping pathologies of insulin resistance, neuroinflammation, and amyloidogenesis in type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD), proposing a framework for dual therapeutic targeting.
Guangyi Xu +8 more
wiley +1 more source